Use of biomarkers sFlt and PlGF in the diagnosis and treatment of pulmonary hypertension

The present invention relates to a method for the diagnosis, early detection and / or risk stratification of pulmonary hypertension in a subject and / or monitoring a treatment of such a disease in a subject comprising quantifying at least one component of the vascular endothelial growth factor (VEGF) signaling pathway as a biomarker , in particular quantifying the biomarker soluble Fms-like tyrosine kinase-1 (sFlt) and / or placental growth factor (PlGF). The invention further relates to a diagnostic kit for performing the method according to the invention, and its use.